Key clinical point: Etanercept was safe and effective with low rates of adverse events and led to better clinical outcomes in children with juvenile psoriatic arthritis (JPsA).

Major finding: The overall incidence of adverse events of special interest and serious adverse events were low and included 3 cases of uveitis (incidence rate [IR]/100 person-years 0.55; 95% CI 0.18-1.69), 1 of neuropathy (IR/100 person-years 0.18; 95% CI 0.03-1.29), and 1 of malignancy (IR/100 person-years 0.13; 95% CI 0.02-0.90). The American College of Rheumatology provisional criteria for inactive disease were achieved by 51.9% and 43.8% of patients at 6- and 12-month follow-ups.

Study details: This study included 226 patients with JPsA (aged ≥2 to <18 years) who received etanercept.

Disclosures: This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc. S Stryker and D Collier declared being employees of and owning stocks in Amgen. SJ Balevic and T Beukelman declared receiving grants or research support, honoraria, or consulting fees or participating in data safety monitoring boards for various sources. The other authors declared no conflicts of interest.

Source: Correll CK et al. Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry. RMD Open. 2023;9:e002943 (May 25). doi: 10.1136/rmdopen-2022-002943

Key clinical point: Etanercept was safe and effective with low rates of adverse events and led to better clinical outcomes in children with juvenile psoriatic arthritis (JPsA).

Major finding: The overall incidence of adverse events of special interest and serious adverse events were low and included 3 cases of uveitis (incidence rate [IR]/100 person-years 0.55; 95% CI 0.18-1.69), 1 of neuropathy (IR/100 person-years 0.18; 95% CI 0.03-1.29), and 1 of malignancy (IR/100 person-years 0.13; 95% CI 0.02-0.90). The American College of Rheumatology provisional criteria for inactive disease were achieved by 51.9% and 43.8% of patients at 6- and 12-month follow-ups.

Study details: This study included 226 patients with JPsA (aged ≥2 to <18 years) who received etanercept.

Disclosures: This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc. S Stryker and D Collier declared being employees of and owning stocks in Amgen. SJ Balevic and T Beukelman declared receiving grants or research support, honoraria, or consulting fees or participating in data safety monitoring boards for various sources. The other authors declared no conflicts of interest.

Source: Correll CK et al. Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry. RMD Open. 2023;9:e002943 (May 25). doi: 10.1136/rmdopen-2022-002943

Key clinical point: Etanercept was safe and effective with low rates of adverse events and led to better clinical outcomes in children with juvenile psoriatic arthritis (JPsA).

Major finding: The overall incidence of adverse events of special interest and serious adverse events were low and included 3 cases of uveitis (incidence rate [IR]/100 person-years 0.55; 95% CI 0.18-1.69), 1 of neuropathy (IR/100 person-years 0.18; 95% CI 0.03-1.29), and 1 of malignancy (IR/100 person-years 0.13; 95% CI 0.02-0.90). The American College of Rheumatology provisional criteria for inactive disease were achieved by 51.9% and 43.8% of patients at 6- and 12-month follow-ups.

Study details: This study included 226 patients with JPsA (aged ≥2 to <18 years) who received etanercept.

Disclosures: This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc. S Stryker and D Collier declared being employees of and owning stocks in Amgen. SJ Balevic and T Beukelman declared receiving grants or research support, honoraria, or consulting fees or participating in data safety monitoring boards for various sources. The other authors declared no conflicts of interest.

Source: Correll CK et al. Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry. RMD Open. 2023;9:e002943 (May 25). doi: 10.1136/rmdopen-2022-002943

Key clinical point: Patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) who initiated methotrexate showed similar rates of methotrexate retention; however, the addition of any other disease-modifying antirheumatic drugs (DMARD) to the treatment regimen was more rapid in RA vs PsA.

Major finding: Overall, 71% of patients with PsA and 76% of patients with RA remained on methotrexate at 2 years after initiating methotrexate. The risk for adding any other DMARD to the treatment regimen was greater in the RA vs PsA group (adjusted hazard ratio 0.86; 95% CI 0.77-0.96), with methotrexate monotherapy improving disease activity in both the groups.

Study details: This observational study included DMARD-naive patients with newly diagnosed PsA (n = 3642) who initiated methotrexate and matched comparator patients with RA (n = 3642).

Disclosures: This study was funded by grants from the Swedish Rheumatism Association and others. Some authors declared serving as consultants or receiving lecture fees, speakers’ bureau fees, or research support from various sources.

Source: Lindström U et al. Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: An observational nationwide study. RMD Open. 2023;9:e002883 (May 12). doi: 10.1136/rmdopen-2022-002883

Key clinical point: Patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) who initiated methotrexate showed similar rates of methotrexate retention; however, the addition of any other disease-modifying antirheumatic drugs (DMARD) to the treatment regimen was more rapid in RA vs PsA.

Major finding: Overall, 71% of patients with PsA and 76% of patients with RA remained on methotrexate at 2 years after initiating methotrexate. The risk for adding any other DMARD to the treatment regimen was greater in the RA vs PsA group (adjusted hazard ratio 0.86; 95% CI 0.77-0.96), with methotrexate monotherapy improving disease activity in both the groups.

Study details: This observational study included DMARD-naive patients with newly diagnosed PsA (n = 3642) who initiated methotrexate and matched comparator patients with RA (n = 3642).

Disclosures: This study was funded by grants from the Swedish Rheumatism Association and others. Some authors declared serving as consultants or receiving lecture fees, speakers’ bureau fees, or research support from various sources.

Source: Lindström U et al. Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: An observational nationwide study. RMD Open. 2023;9:e002883 (May 12). doi: 10.1136/rmdopen-2022-002883

Key clinical point: Patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) who initiated methotrexate showed similar rates of methotrexate retention; however, the addition of any other disease-modifying antirheumatic drugs (DMARD) to the treatment regimen was more rapid in RA vs PsA.

Major finding: Overall, 71% of patients with PsA and 76% of patients with RA remained on methotrexate at 2 years after initiating methotrexate. The risk for adding any other DMARD to the treatment regimen was greater in the RA vs PsA group (adjusted hazard ratio 0.86; 95% CI 0.77-0.96), with methotrexate monotherapy improving disease activity in both the groups.

Study details: This observational study included DMARD-naive patients with newly diagnosed PsA (n = 3642) who initiated methotrexate and matched comparator patients with RA (n = 3642).

Disclosures: This study was funded by grants from the Swedish Rheumatism Association and others. Some authors declared serving as consultants or receiving lecture fees, speakers’ bureau fees, or research support from various sources.

Source: Lindström U et al. Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: An observational nationwide study. RMD Open. 2023;9:e002883 (May 12). doi: 10.1136/rmdopen-2022-002883

Key clinical point: Brepocitinib, the tyrosine kinase 2/Janus kinase 1 inhibitor, was superior to placebo in reducing signs and symptoms of psoriatic arthritis (PsA) and was well-tolerated throughout the 52-week study period.

Major finding: At week 16, American College of Rheumatology 20 response was achieved by a significantly higher proportion of patients receiving brepocitinib at doses of 30 mg (66.7%; P = .0197) and 60 mg (74.6%; P = .0006) compared with placebo (43.3%), with the response being maintained through week 52. Overall, 12 serious adverse events were reported in the brepocitinib arms (30 and 60 mg) by week 52. No deaths were reported.

Study details: Findings are from a phase 2b, dose-ranging, parallel treatment group trial including 218 patients with active PsA who were randomly assigned to receive either brepocitinib (60, 30, or 10 mg once daily) or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Several authors declared being current or former employees and shareholders of Pfizer. The other authors reported ties with various sources, including Pfizer.

Source: Mease P et al. Efficacy and safety of tyrosine kinase 2/Janus kinase 1 Inhibitor brepocitinib for active psoriatic arthritis: A phase IIb randomized controlled trial. Arthritis Rheumatol. 2023 (May 17). doi: 10.1002/art.42519

Key clinical point: Brepocitinib, the tyrosine kinase 2/Janus kinase 1 inhibitor, was superior to placebo in reducing signs and symptoms of psoriatic arthritis (PsA) and was well-tolerated throughout the 52-week study period.

Major finding: At week 16, American College of Rheumatology 20 response was achieved by a significantly higher proportion of patients receiving brepocitinib at doses of 30 mg (66.7%; P = .0197) and 60 mg (74.6%; P = .0006) compared with placebo (43.3%), with the response being maintained through week 52. Overall, 12 serious adverse events were reported in the brepocitinib arms (30 and 60 mg) by week 52. No deaths were reported.

Study details: Findings are from a phase 2b, dose-ranging, parallel treatment group trial including 218 patients with active PsA who were randomly assigned to receive either brepocitinib (60, 30, or 10 mg once daily) or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Several authors declared being current or former employees and shareholders of Pfizer. The other authors reported ties with various sources, including Pfizer.

Source: Mease P et al. Efficacy and safety of tyrosine kinase 2/Janus kinase 1 Inhibitor brepocitinib for active psoriatic arthritis: A phase IIb randomized controlled trial. Arthritis Rheumatol. 2023 (May 17). doi: 10.1002/art.42519

Key clinical point: Brepocitinib, the tyrosine kinase 2/Janus kinase 1 inhibitor, was superior to placebo in reducing signs and symptoms of psoriatic arthritis (PsA) and was well-tolerated throughout the 52-week study period.

Major finding: At week 16, American College of Rheumatology 20 response was achieved by a significantly higher proportion of patients receiving brepocitinib at doses of 30 mg (66.7%; P = .0197) and 60 mg (74.6%; P = .0006) compared with placebo (43.3%), with the response being maintained through week 52. Overall, 12 serious adverse events were reported in the brepocitinib arms (30 and 60 mg) by week 52. No deaths were reported.

Study details: Findings are from a phase 2b, dose-ranging, parallel treatment group trial including 218 patients with active PsA who were randomly assigned to receive either brepocitinib (60, 30, or 10 mg once daily) or placebo.

Disclosures: This study was sponsored by Pfizer Inc. Several authors declared being current or former employees and shareholders of Pfizer. The other authors reported ties with various sources, including Pfizer.

Source: Mease P et al. Efficacy and safety of tyrosine kinase 2/Janus kinase 1 Inhibitor brepocitinib for active psoriatic arthritis: A phase IIb randomized controlled trial. Arthritis Rheumatol. 2023 (May 17). doi: 10.1002/art.42519

Baseline depression was significantly associated with recovered, incident, and persistent metabolic syndrome, based on data from more than 13,000 individuals.

Previous research has established a connection between metabolic syndrome and depression, but data on the increased risk for depressed individuals to develop metabolic syndrome (MetS) are lacking, wrote Lara Onofre Ferriani, PhD, of Federal University of Espírito Santo, Vitoria, Brazil, and colleagues.

“Individuals with MetS and depression have increased levels of inflammatory markers, and it is speculated that inflammation could mediate this comorbidity,” they said.

In a study published in the Journal of Psychiatric Research, the investigators reviewed data from 13,883 participants in the Brazilian Longitudinal Study of Adult Health; all were civil servants at universities in Brazil. The participants ranged from 35 to 74 years of age, with a mean age of 51.9 years; 54.3% were women; and 52.4% were white; the mean follow-up period was 3.8 years.

The primary outcome was the association between depression diagnosis and severity on components of MetS at baseline and over a 4-year period. Participants were classified by MetS trajectory as recovered, incident, or persistent, and classified by depression status as without depression or with a mild, moderate, or severe current depressive episode. Depression status was based on the Clinical Interview Schedule Revised. MetS components and diagnosis were based on the National Cholesterol Education Program Adult Treatment Panel III.

In a logistic regression analysis, baseline depression was positively associated with recovered, incident, and persistent MetS (odds ratios, 1.59, 1.45, and 1.70, respectively).

Depression at baseline also was significantly associated with separate components of MetS: large waist circumference, high triglycerides, low high-density lipoprotein cholesterol, and hyperglycemia, with odds ratios of 1.47, 1.23, 1.30, and 1.38, respectively.

Although not seen at baseline, a significant positive association between baseline depression and the presence of three or more MetS components was noted at follow-up, with a positive dose-response effect, the researchers wrote in their discussion.

Not all associations were statistically significant, but this was mainly because of the small number of cases of moderate and severe depression, they said. However, the magnitude of associations was greater in severe depression, when compared with moderate and mild, which suggests that the risk of MetS may be higher in this population, they added.

The study findings were limited by several factors including the possible misclassification of depression, inability to differentiate among depressive subtypes, and the potential lack of generalizability to other populations beyond Brazilian civil servants, the researchers noted.

However, the results were strengthened by the large sample size and support the role of depression as a risk factor for MetS, they said. More research is needed to determine a bidirectional relationship and to assess the trajectory of depression after MetS develops, but the findings “highlight the need to investigate and manage metabolic and cardiovascular alterations in the presence of depression in clinical settings,” they concluded.

The study was supported by the Brazilian Ministry of Health (Science and Technology Department) and the Brazilian Ministry of Science, Technology and Innovation FINEP and CNPq, and by the Coordenaçaõ de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES). The researchers had no financial conflicts to disclose.
 

Baseline depression was significantly associated with recovered, incident, and persistent metabolic syndrome, based on data from more than 13,000 individuals.

Previous research has established a connection between metabolic syndrome and depression, but data on the increased risk for depressed individuals to develop metabolic syndrome (MetS) are lacking, wrote Lara Onofre Ferriani, PhD, of Federal University of Espírito Santo, Vitoria, Brazil, and colleagues.

“Individuals with MetS and depression have increased levels of inflammatory markers, and it is speculated that inflammation could mediate this comorbidity,” they said.

In a study published in the Journal of Psychiatric Research, the investigators reviewed data from 13,883 participants in the Brazilian Longitudinal Study of Adult Health; all were civil servants at universities in Brazil. The participants ranged from 35 to 74 years of age, with a mean age of 51.9 years; 54.3% were women; and 52.4% were white; the mean follow-up period was 3.8 years.

The primary outcome was the association between depression diagnosis and severity on components of MetS at baseline and over a 4-year period. Participants were classified by MetS trajectory as recovered, incident, or persistent, and classified by depression status as without depression or with a mild, moderate, or severe current depressive episode. Depression status was based on the Clinical Interview Schedule Revised. MetS components and diagnosis were based on the National Cholesterol Education Program Adult Treatment Panel III.

In a logistic regression analysis, baseline depression was positively associated with recovered, incident, and persistent MetS (odds ratios, 1.59, 1.45, and 1.70, respectively).

Depression at baseline also was significantly associated with separate components of MetS: large waist circumference, high triglycerides, low high-density lipoprotein cholesterol, and hyperglycemia, with odds ratios of 1.47, 1.23, 1.30, and 1.38, respectively.

Although not seen at baseline, a significant positive association between baseline depression and the presence of three or more MetS components was noted at follow-up, with a positive dose-response effect, the researchers wrote in their discussion.

Not all associations were statistically significant, but this was mainly because of the small number of cases of moderate and severe depression, they said. However, the magnitude of associations was greater in severe depression, when compared with moderate and mild, which suggests that the risk of MetS may be higher in this population, they added.

The study findings were limited by several factors including the possible misclassification of depression, inability to differentiate among depressive subtypes, and the potential lack of generalizability to other populations beyond Brazilian civil servants, the researchers noted.

However, the results were strengthened by the large sample size and support the role of depression as a risk factor for MetS, they said. More research is needed to determine a bidirectional relationship and to assess the trajectory of depression after MetS develops, but the findings “highlight the need to investigate and manage metabolic and cardiovascular alterations in the presence of depression in clinical settings,” they concluded.

The study was supported by the Brazilian Ministry of Health (Science and Technology Department) and the Brazilian Ministry of Science, Technology and Innovation FINEP and CNPq, and by the Coordenaçaõ de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES). The researchers had no financial conflicts to disclose.
 

Baseline depression was significantly associated with recovered, incident, and persistent metabolic syndrome, based on data from more than 13,000 individuals.

Previous research has established a connection between metabolic syndrome and depression, but data on the increased risk for depressed individuals to develop metabolic syndrome (MetS) are lacking, wrote Lara Onofre Ferriani, PhD, of Federal University of Espírito Santo, Vitoria, Brazil, and colleagues.

“Individuals with MetS and depression have increased levels of inflammatory markers, and it is speculated that inflammation could mediate this comorbidity,” they said.

In a study published in the Journal of Psychiatric Research, the investigators reviewed data from 13,883 participants in the Brazilian Longitudinal Study of Adult Health; all were civil servants at universities in Brazil. The participants ranged from 35 to 74 years of age, with a mean age of 51.9 years; 54.3% were women; and 52.4% were white; the mean follow-up period was 3.8 years.

The primary outcome was the association between depression diagnosis and severity on components of MetS at baseline and over a 4-year period. Participants were classified by MetS trajectory as recovered, incident, or persistent, and classified by depression status as without depression or with a mild, moderate, or severe current depressive episode. Depression status was based on the Clinical Interview Schedule Revised. MetS components and diagnosis were based on the National Cholesterol Education Program Adult Treatment Panel III.

In a logistic regression analysis, baseline depression was positively associated with recovered, incident, and persistent MetS (odds ratios, 1.59, 1.45, and 1.70, respectively).

Depression at baseline also was significantly associated with separate components of MetS: large waist circumference, high triglycerides, low high-density lipoprotein cholesterol, and hyperglycemia, with odds ratios of 1.47, 1.23, 1.30, and 1.38, respectively.

Although not seen at baseline, a significant positive association between baseline depression and the presence of three or more MetS components was noted at follow-up, with a positive dose-response effect, the researchers wrote in their discussion.

Not all associations were statistically significant, but this was mainly because of the small number of cases of moderate and severe depression, they said. However, the magnitude of associations was greater in severe depression, when compared with moderate and mild, which suggests that the risk of MetS may be higher in this population, they added.

The study findings were limited by several factors including the possible misclassification of depression, inability to differentiate among depressive subtypes, and the potential lack of generalizability to other populations beyond Brazilian civil servants, the researchers noted.

However, the results were strengthened by the large sample size and support the role of depression as a risk factor for MetS, they said. More research is needed to determine a bidirectional relationship and to assess the trajectory of depression after MetS develops, but the findings “highlight the need to investigate and manage metabolic and cardiovascular alterations in the presence of depression in clinical settings,” they concluded.

The study was supported by the Brazilian Ministry of Health (Science and Technology Department) and the Brazilian Ministry of Science, Technology and Innovation FINEP and CNPq, and by the Coordenaçaõ de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES). The researchers had no financial conflicts to disclose.
 

Key clinical point: Higher genetic susceptibility to breast cancer (BC) is associated with an increased risk for overall thyroid cancer; however, this association is not valid in case of triple-negative BC (TNBC) and thyroid cancer.

Major finding: The risk for thyroid cancer was significantly elevated in patients with BC (odds ratio 1.135; P = .038); however, no causal link was observed between TNBC and thyroid cancer (OR 0.817; P = .177).

Study details: Findings are from a two-sample mendelian randomization analysis including 133,384 patients with BC and 113,789 BC-free control individuals.

Disclosures: This study was supported by funding from the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Tan H et al. Association between breast cancer and thyroid cancer risk: A two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2023;14:1138149 (May 23). doi: 10.3389/fendo.2023.1138149

Key clinical point: Higher genetic susceptibility to breast cancer (BC) is associated with an increased risk for overall thyroid cancer; however, this association is not valid in case of triple-negative BC (TNBC) and thyroid cancer.

Major finding: The risk for thyroid cancer was significantly elevated in patients with BC (odds ratio 1.135; P = .038); however, no causal link was observed between TNBC and thyroid cancer (OR 0.817; P = .177).

Study details: Findings are from a two-sample mendelian randomization analysis including 133,384 patients with BC and 113,789 BC-free control individuals.

Disclosures: This study was supported by funding from the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Tan H et al. Association between breast cancer and thyroid cancer risk: A two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2023;14:1138149 (May 23). doi: 10.3389/fendo.2023.1138149

Key clinical point: Higher genetic susceptibility to breast cancer (BC) is associated with an increased risk for overall thyroid cancer; however, this association is not valid in case of triple-negative BC (TNBC) and thyroid cancer.

Major finding: The risk for thyroid cancer was significantly elevated in patients with BC (odds ratio 1.135; P = .038); however, no causal link was observed between TNBC and thyroid cancer (OR 0.817; P = .177).

Study details: Findings are from a two-sample mendelian randomization analysis including 133,384 patients with BC and 113,789 BC-free control individuals.

Disclosures: This study was supported by funding from the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Tan H et al. Association between breast cancer and thyroid cancer risk: A two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2023;14:1138149 (May 23). doi: 10.3389/fendo.2023.1138149

Key clinical point: In patients with early-stage breast cancer (BC), breast conserving surgery with radiotherapy (BCT) provided a significant survival advantage over total mastectomy (TM) without increasing the rates of locoregional recurrence.

Major finding: BCT vs TM improved overall survival by 37% (hazard ratio [HR] 1.37; P < .001) and BC-specific survival by 49% (HR 1.49; P < .001), with rates of locoregional recurrence (P > .9) being comparable between the groups.

Study details: This study analyzed the data of 12,456 patients with pT1-2 pN0 BC from a prospectively maintained database, of which 8422 and 4034 patients underwent BCT and TM, respectively.

Disclosures: This study did not report the source of funding. The authors did not report any conflicts of interest.

Source: Vasilyeva E et al. Breast conserving surgery combined with radiation therapy offers improved survival over mastectomy in early-stage breast cancer. Am J Surg. 2023 (May 22). doi: 10.1016/j.amjsurg.2023.05.005

Key clinical point: In patients with early-stage breast cancer (BC), breast conserving surgery with radiotherapy (BCT) provided a significant survival advantage over total mastectomy (TM) without increasing the rates of locoregional recurrence.

Major finding: BCT vs TM improved overall survival by 37% (hazard ratio [HR] 1.37; P < .001) and BC-specific survival by 49% (HR 1.49; P < .001), with rates of locoregional recurrence (P > .9) being comparable between the groups.

Study details: This study analyzed the data of 12,456 patients with pT1-2 pN0 BC from a prospectively maintained database, of which 8422 and 4034 patients underwent BCT and TM, respectively.

Disclosures: This study did not report the source of funding. The authors did not report any conflicts of interest.

Source: Vasilyeva E et al. Breast conserving surgery combined with radiation therapy offers improved survival over mastectomy in early-stage breast cancer. Am J Surg. 2023 (May 22). doi: 10.1016/j.amjsurg.2023.05.005

Key clinical point: In patients with early-stage breast cancer (BC), breast conserving surgery with radiotherapy (BCT) provided a significant survival advantage over total mastectomy (TM) without increasing the rates of locoregional recurrence.

Major finding: BCT vs TM improved overall survival by 37% (hazard ratio [HR] 1.37; P < .001) and BC-specific survival by 49% (HR 1.49; P < .001), with rates of locoregional recurrence (P > .9) being comparable between the groups.

Study details: This study analyzed the data of 12,456 patients with pT1-2 pN0 BC from a prospectively maintained database, of which 8422 and 4034 patients underwent BCT and TM, respectively.

Disclosures: This study did not report the source of funding. The authors did not report any conflicts of interest.

Source: Vasilyeva E et al. Breast conserving surgery combined with radiation therapy offers improved survival over mastectomy in early-stage breast cancer. Am J Surg. 2023 (May 22). doi: 10.1016/j.amjsurg.2023.05.005

Key clinical point: Men with a family history of breast cancer (FHBC) in either mother or sister are at a higher risk of developing pancreatic, thyroid, prostate, and breast cancers than men without FHBC and, therefore, may need more vigilant cancer surveillance.

Major finding: An FHBC in both mother and sister was associated with an increased overall cancer risk (hazard ratio [HR] 1.69; 95% CI 1.11-2.57), whereas an FHBC in either mother or sister significantly increased the risk of developing pancreatic cancer (HR 1.35; 95% CI 1.07-1.70), breast cancer (HR 3.03; 95% CI 1.13-8.17), thyroid cancer (HR 1.33; 95% CI 1.12-1.56), and prostate cancer (HR 1.28; 95% CI 1.13-1.44).

Study details: Findings are from a population-based study including 2,734,889 men aged ≥40 years, of which 69,124 men had a FHBC in their mother or sister and 276,496 men had no history of cancer in any of their first-degree relatives.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Song H, Jung YS, et al. Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study. Int J Cancer. 2023 (May 29). doi: 10.1002/ijc.34573

Key clinical point: Men with a family history of breast cancer (FHBC) in either mother or sister are at a higher risk of developing pancreatic, thyroid, prostate, and breast cancers than men without FHBC and, therefore, may need more vigilant cancer surveillance.

Major finding: An FHBC in both mother and sister was associated with an increased overall cancer risk (hazard ratio [HR] 1.69; 95% CI 1.11-2.57), whereas an FHBC in either mother or sister significantly increased the risk of developing pancreatic cancer (HR 1.35; 95% CI 1.07-1.70), breast cancer (HR 3.03; 95% CI 1.13-8.17), thyroid cancer (HR 1.33; 95% CI 1.12-1.56), and prostate cancer (HR 1.28; 95% CI 1.13-1.44).

Study details: Findings are from a population-based study including 2,734,889 men aged ≥40 years, of which 69,124 men had a FHBC in their mother or sister and 276,496 men had no history of cancer in any of their first-degree relatives.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Song H, Jung YS, et al. Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study. Int J Cancer. 2023 (May 29). doi: 10.1002/ijc.34573

Key clinical point: Men with a family history of breast cancer (FHBC) in either mother or sister are at a higher risk of developing pancreatic, thyroid, prostate, and breast cancers than men without FHBC and, therefore, may need more vigilant cancer surveillance.

Major finding: An FHBC in both mother and sister was associated with an increased overall cancer risk (hazard ratio [HR] 1.69; 95% CI 1.11-2.57), whereas an FHBC in either mother or sister significantly increased the risk of developing pancreatic cancer (HR 1.35; 95% CI 1.07-1.70), breast cancer (HR 3.03; 95% CI 1.13-8.17), thyroid cancer (HR 1.33; 95% CI 1.12-1.56), and prostate cancer (HR 1.28; 95% CI 1.13-1.44).

Study details: Findings are from a population-based study including 2,734,889 men aged ≥40 years, of which 69,124 men had a FHBC in their mother or sister and 276,496 men had no history of cancer in any of their first-degree relatives.

Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.

Source: Song H, Jung YS, et al. Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study. Int J Cancer. 2023 (May 29). doi: 10.1002/ijc.34573

Key clinical point: Low vs no human epidermal growth factor receptor 2 (ERBB2, aka HER2) expression had no impact on survival outcomes in patients with hormone receptor-positive (HR+) metastatic breast cancer (BC) who were treated with targeted therapy (TT) plus endocrine therapy (ET).

Major finding: After a median follow-up of 17.9 months, both progression-free survival (P = .43) and overall survival (P = .41) were not significantly different between patients with low and no ERBB2 expression.

Study details: Findings are from an analysis of 1585 patients with HR+ metastatic BC treated with TT+ET from an institutional review board-approved breast cancer database, of which 572 and 1013 patients had no and low ERBB2 expression, respectively.

Disclosures: This study was supported by the National Cancer Institute and other sources. Some authors declared receiving personal fees, grants, or nonfinancial support from several sources.

Source: Mouabbi JA et al. Survival outcomes in patients with hormone receptor-positive metastatic breast cancer with low or no ERBB2 expression treated with targeted therapies plus endocrine therapy. JAMA Netw Open. 2023;6:e2313017 (May 11). doi: 10.1001/jamanetworkopen.2023.13017

Key clinical point: Low vs no human epidermal growth factor receptor 2 (ERBB2, aka HER2) expression had no impact on survival outcomes in patients with hormone receptor-positive (HR+) metastatic breast cancer (BC) who were treated with targeted therapy (TT) plus endocrine therapy (ET).

Major finding: After a median follow-up of 17.9 months, both progression-free survival (P = .43) and overall survival (P = .41) were not significantly different between patients with low and no ERBB2 expression.

Study details: Findings are from an analysis of 1585 patients with HR+ metastatic BC treated with TT+ET from an institutional review board-approved breast cancer database, of which 572 and 1013 patients had no and low ERBB2 expression, respectively.

Disclosures: This study was supported by the National Cancer Institute and other sources. Some authors declared receiving personal fees, grants, or nonfinancial support from several sources.

Source: Mouabbi JA et al. Survival outcomes in patients with hormone receptor-positive metastatic breast cancer with low or no ERBB2 expression treated with targeted therapies plus endocrine therapy. JAMA Netw Open. 2023;6:e2313017 (May 11). doi: 10.1001/jamanetworkopen.2023.13017

Key clinical point: Low vs no human epidermal growth factor receptor 2 (ERBB2, aka HER2) expression had no impact on survival outcomes in patients with hormone receptor-positive (HR+) metastatic breast cancer (BC) who were treated with targeted therapy (TT) plus endocrine therapy (ET).

Major finding: After a median follow-up of 17.9 months, both progression-free survival (P = .43) and overall survival (P = .41) were not significantly different between patients with low and no ERBB2 expression.

Study details: Findings are from an analysis of 1585 patients with HR+ metastatic BC treated with TT+ET from an institutional review board-approved breast cancer database, of which 572 and 1013 patients had no and low ERBB2 expression, respectively.

Disclosures: This study was supported by the National Cancer Institute and other sources. Some authors declared receiving personal fees, grants, or nonfinancial support from several sources.

Source: Mouabbi JA et al. Survival outcomes in patients with hormone receptor-positive metastatic breast cancer with low or no ERBB2 expression treated with targeted therapies plus endocrine therapy. JAMA Netw Open. 2023;6:e2313017 (May 11). doi: 10.1001/jamanetworkopen.2023.13017

Key clinical point: In postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were disease free after 5 years of endocrine therapy (ET), extended adjuvant treatment with letrozole for 5 years led to improved disease-free survival (DFS) at >10-year median follow-up.

Major finding: After median follow-up of 10.3 years, letrozole vs placebo significantly improved DFS (10-year absolute benefit 3.4%; hazard ratio 0.85; P = .01). There were no notable differences in toxicity outcomes between the groups.

Study details: Findings are from the phase 3 National Surgical Adjuvant Breast and Bowel Project B-42 trial including 3966 postmenopausal women with stage I-IIIA HR+ BC who were disease free after 5 years of adjuvant ET and were randomly assigned to receive letrozole or placebo for 5 more years.

Disclosures: This study was funded by Novartis and others. Some authors declared receiving grants, honoraria, travel support, or consulting fees or serving on advisory boards or data and safety monitoring boards for various sources, including Novartis.

Source: Mamounas EP et al. Ten-year update: NRG Oncology/NSABP B-42 randomized trial: Extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst. 2023 (May 15). doi: 10.1093/jnci/djad078

Key clinical point: In postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were disease free after 5 years of endocrine therapy (ET), extended adjuvant treatment with letrozole for 5 years led to improved disease-free survival (DFS) at >10-year median follow-up.

Major finding: After median follow-up of 10.3 years, letrozole vs placebo significantly improved DFS (10-year absolute benefit 3.4%; hazard ratio 0.85; P = .01). There were no notable differences in toxicity outcomes between the groups.

Study details: Findings are from the phase 3 National Surgical Adjuvant Breast and Bowel Project B-42 trial including 3966 postmenopausal women with stage I-IIIA HR+ BC who were disease free after 5 years of adjuvant ET and were randomly assigned to receive letrozole or placebo for 5 more years.

Disclosures: This study was funded by Novartis and others. Some authors declared receiving grants, honoraria, travel support, or consulting fees or serving on advisory boards or data and safety monitoring boards for various sources, including Novartis.

Source: Mamounas EP et al. Ten-year update: NRG Oncology/NSABP B-42 randomized trial: Extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst. 2023 (May 15). doi: 10.1093/jnci/djad078

Key clinical point: In postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were disease free after 5 years of endocrine therapy (ET), extended adjuvant treatment with letrozole for 5 years led to improved disease-free survival (DFS) at >10-year median follow-up.

Major finding: After median follow-up of 10.3 years, letrozole vs placebo significantly improved DFS (10-year absolute benefit 3.4%; hazard ratio 0.85; P = .01). There were no notable differences in toxicity outcomes between the groups.

Study details: Findings are from the phase 3 National Surgical Adjuvant Breast and Bowel Project B-42 trial including 3966 postmenopausal women with stage I-IIIA HR+ BC who were disease free after 5 years of adjuvant ET and were randomly assigned to receive letrozole or placebo for 5 more years.

Disclosures: This study was funded by Novartis and others. Some authors declared receiving grants, honoraria, travel support, or consulting fees or serving on advisory boards or data and safety monitoring boards for various sources, including Novartis.

Source: Mamounas EP et al. Ten-year update: NRG Oncology/NSABP B-42 randomized trial: Extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst. 2023 (May 15). doi: 10.1093/jnci/djad078

Key clinical point: Adding cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) improved survival outcomes in elderly patients aged ≥65 years with advanced estrogen receptor-positive (ER+) breast cancer (BC).

Major finding: Adding CDK4/6 inhibitors to ET (letrozole or fulvestrant) significantly reduced the mortality risk by 21% (hazard ratio [HR] 0.79; 95% CI 0.69-0.91) and progression risk by 41% (HR 0.59; 95% CI 0.51-0.69) in older patients aged >65 years with BC.

Study details: Findings are from a meta-analysis of 10 trials including 1985 older patients with advanced ER+ BC who received ET with or without CDK4/6 inhibitors.

Disclosures: This study did not report the source of funding. The authors did not declare any conflicts of interest.

Source: Petrelli F et al. The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis. Breast. 2023 (May 12). doi: 10.1016/j.breast.2023.05.002

Key clinical point: Adding cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) improved survival outcomes in elderly patients aged ≥65 years with advanced estrogen receptor-positive (ER+) breast cancer (BC).

Major finding: Adding CDK4/6 inhibitors to ET (letrozole or fulvestrant) significantly reduced the mortality risk by 21% (hazard ratio [HR] 0.79; 95% CI 0.69-0.91) and progression risk by 41% (HR 0.59; 95% CI 0.51-0.69) in older patients aged >65 years with BC.

Study details: Findings are from a meta-analysis of 10 trials including 1985 older patients with advanced ER+ BC who received ET with or without CDK4/6 inhibitors.

Disclosures: This study did not report the source of funding. The authors did not declare any conflicts of interest.

Source: Petrelli F et al. The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis. Breast. 2023 (May 12). doi: 10.1016/j.breast.2023.05.002

Key clinical point: Adding cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) improved survival outcomes in elderly patients aged ≥65 years with advanced estrogen receptor-positive (ER+) breast cancer (BC).

Major finding: Adding CDK4/6 inhibitors to ET (letrozole or fulvestrant) significantly reduced the mortality risk by 21% (hazard ratio [HR] 0.79; 95% CI 0.69-0.91) and progression risk by 41% (HR 0.59; 95% CI 0.51-0.69) in older patients aged >65 years with BC.

Study details: Findings are from a meta-analysis of 10 trials including 1985 older patients with advanced ER+ BC who received ET with or without CDK4/6 inhibitors.

Disclosures: This study did not report the source of funding. The authors did not declare any conflicts of interest.

Source: Petrelli F et al. The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis. Breast. 2023 (May 12). doi: 10.1016/j.breast.2023.05.002